Tocagen’s initial proposed indication, recurrent high-grade glioma, or HGG, is the most common and aggressive primary brain cancer. The two most common forms of HGG are glioblastoma and anaplastic astrocytoma. HGG recurs in most patients, even after maximal treatment. Participation in a clinical trial is one possible option for people who have regrowth of these types of brain cancers. It is recommended that patients talk with their doctor to discuss potential participation in a clinical trial.
Tocagen’s Phase 3 clinical trial, called Toca 5, for patients with recurrent HGG is fully enrolled.
Toca 511 & Toca FC are investigational products. An investigational product is one that has not been proven to be safe and effective and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.